Piperacillin

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, EPS, Task force, DNA, Nursing care plan, Piperacillin, Noise, Corporate social responsibility, FDA, Corporation, Medicine, UN, Dow Jones, EMR, Failure, Baxter International, Growth, Perioperative, TCFD, DJSI, Patient, Tazobactam, Centrella, Skin, Thrombin, Risk, Warburg Pincus, Acute liver failure, Galaxy, PD, NuVasive, Peritoneal dialysis, Risk management, Advent International, BPS, Sale, Eye, CST, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
  • For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
  • In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
  • For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.

Baxter Reports Third-Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, General Health, Health, Medical Devices, Health Technology, Baxter, Warburg Pincus, Tazobactam, BVLOS drone medical delivery trials in India, Piperacillin, Growth, EPS, Risk, BPS, Advent International, Medicine, Breakout Labs, EMR, Eye, Patient, Peritoneal dialysis, CDT, Pharmaceutical industry, Cassette tape, Fine chemical, Hemodialysis, Medication

Under the terms of the definitive agreement, Baxter received total proceeds of $4.25 billion, subject to adjustment for specified items.

Key Points: 
  • Under the terms of the definitive agreement, Baxter received total proceeds of $4.25 billion, subject to adjustment for specified items.
  • Baxter currently expects the Kidney Care spinoff to occur by July 2024 or earlier, subject to the satisfaction of customary conditions.
  • Baxter expects sales growth from continuing operations of 1% to 2% on a reported basis and approximately 1% on a constant currency basis.
  • A webcast of Baxter’s third-quarter 2023 conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on Nov. 2, 2023.

Baxter Reports First-Quarter 2023 Results

Retrieved on: 
Thursday, April 27, 2023
Biotechnology, Managed Care, Medical Supplies, Surgery, Health, Medical Devices, Hospitals, Fitness & Nutrition, Galaxy, DNA, ALF, Agility, Noise, Piperacillin, Fort Robinson breakout, Pump, Baxter, COVID-19, Thrombin, IQ, GAAP, Baxter International, U.S. FDA, Tazobactam, Acute liver failure, Information International, Inc., Hospital, Patient, Generally Accepted Accounting Principles (United States), Injection, Novum, Liver, Growth, CDT, SYR, NYSE, LVP, Cryptocurrency, Fine chemical, Pharmaceutical industry, Management, Security (finance)

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
  • On an adjusted basis, net income attributable to Baxter totaled $297 million, or $0.59 per diluted share, a 37% decrease.
  • Baxter expects to report quarterly performance in line with the new operating model beginning in the second half of 2023.
  • Among recent corporate responsibility highlights, Baxter and the Baxter International Foundation advanced support for disaster relief in response to February’s devastating earthquake in Turkey and Syria.

Baxter Launches Zosyn Premix in US

Retrieved on: 
Tuesday, April 4, 2023
Medical Supplies, Health, Hospitals, Other Health, Managed Care, Pharmaceutical, Biotechnology, Baxter, Piperacillin, Baxter International, Tazobactam, Information International, Inc., Galaxy, Patient, NYSE, Patient safety, Injection, Pharmaceutical industry, Medication

Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.

Key Points: 
  • Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.
  • “Zosyn premix is an important addition to Baxter’s portfolio of valuable anti-infective medications that help treat some of the most pressing healthcare needs facing patients today,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter.
  • Baxter will sell Zosyn premix in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100mL presentations.
  • Like other medications in Baxter’s premix portfolio, Zosyn premix uses Baxter’s proprietary Galaxy container technology.

InsightRX Provides Máxima Medical Center with Precision Dosing Guidance

Retrieved on: 
Tuesday, December 13, 2022
Doctor of Pharmacy, Physician, Azole, Algorithm, Software, Acute kidney injury, Tacrolimus, Doctor of Philosophy, Piperacillin, Magnetic resonance, Partnership, IBD, Patient, Research, Hospital, Precision medicine, Therapeutic drug monitoring, Voriconazole, Sunitinib, Inflammatory bowel disease, City, Meropenem, Adalimumab, MMC, SAN, Machine learning, Vancomycin, Methotrexate, Organization, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, Dec. 13, 2022 /PRNewswire/ -- Today InsightRX, a precision dosing intelligence company, announced that Máxima Medical Center (MMC), a 600-bed teaching hospital in the Netherlands, is using its cloud-based precision dosing platform to support its clinical practice and immunology research. The center relies on the InsightRX Nova platform to support accurate therapeutic drug monitoring of the antibiotic drugs vancomycin and aminoglycoside for adults, children, and neonates. Through an innovative research partnership, InsightRX Nova also provides MMC with precision dosing support and analytics for the monoclonal antibodies infliximab and adalimumab, used in the treatment of Inflammatory Bowel Disease (IBD).

Key Points: 
  • SAN FRANCISCO, Dec. 13, 2022 /PRNewswire/ -- Today InsightRX, a precision dosing intelligence company, announced that Mxima Medical Center (MMC), a 600-bed teaching hospital in the Netherlands, is using its cloud-based precision dosing platform to support its clinical practice and immunology research.
  • Through an innovative research partnership, InsightRX Nova also provides MMC with precision dosing support and analytics for the monoclonal antibodies infliximab and adalimumab, used in the treatment of Inflammatory Bowel Disease (IBD).
  • Now, the days of simply doubling the dose when patients prove nonresponsive to treatment are over," said Luc Derijks, PharmD, PhD, clinical pharmacologist at Mxima Medical Center.
  • "We look forward to a long partnership with Mxima Medical Center, which has embraced the benefits of both reactive and proactive therapeutic drug monitoring," said Sirj Goswami, CEO and co-founder of InsightRX.

Global Piperacillin Sodium (CAS 59703 84 3) Market Report 2022: A $ 209.8 Million Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 14, 2022
Health, Pharmaceutical, Oblasts of Russia, Piperacillin, CAS, Phosphorus

Overview of the regional outlook of the Piperacillin Sodium(CAS 59703 84 3) Market:

Key Points: 

Overview of the regional outlook of the Piperacillin Sodium(CAS 59703 84 3) Market:
3.3 Piperacillin Sodium(CAS 59703 84 3) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Manufacturers Piperacillin Sodium(CAS 59703 84 3) Sales Sites, Area Served, Product Type

Insights on the Penicillin Drug Global Market to 2026 - Featuring Qiagen, Illumina and Hologic Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 19, 2022
Health, Pharmaceutical, CDC, Mortality, Esbly, Patient, UNICEF, Combination therapy, Korea Disease Control and Prevention Agency, Spectrum, Center, Incidence, Ticarcillin, Gram-negative bacteria, Penicillin, Malaria, Piperacillin, Virus, Disease, Diarrhea, Death, Population, American Thoracic Society, CAP, Bacteria, Infection, Fungus, Staphylococcus, Staphylococcus aureus, Community-acquired pneumonia, Risk, ICU, Antibiotics, Vaccine, Pneumonia, Child, Epidemiology, Mezlocillin

These are groups of semi-synthetic penicillin antibiotics that, because of their chemical structure, have a wider spectrum of activity than natural penicillins.

Key Points: 
  • These are groups of semi-synthetic penicillin antibiotics that, because of their chemical structure, have a wider spectrum of activity than natural penicillins.
  • They are more active against Gram-negative bacteria because they are more resistant to inactivation by extended-spectrum ?-lactamases (ESBLs) produced by these Gram-negative bacteria.
  • The increasing incidence of infectious diseases is predicted to accelerate the market for these penicillin drugs.
  • North America holds the major market share in the Penicillin Drug market and is expected to dominate the overall market throughout the forecast period.

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, February 25, 2020
Medical specialties, Medicine, Health, Infectious diseases, Penicillins, Beta-lactamase inhibitors, Diketopiperazines, Piperacillin, Wyeth, Tazobactam, Hospital-acquired infection, Urinary tract infection

Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).

Key Points: 
  • Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).
  • Treatment discontinuations were seen at comparable levels in 5.2% and 4.0% in EXBLIFEP and piperacillin-tazobactam respectively.
  • HAP is the second most common nosocomial infection (after urinary tract infections) and accounts for 1520% of the total.
  • Allecra is supported by Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMed Partners.

FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Retrieved on: 
Monday, June 3, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, FDA, Bacteria, Organic compounds, Chemical compounds, RTT, Penicillins, Gram-negative bacteria, Pseudomonadales, Antibiotic-resistant bacteria, Piperacillin, Tazobactam, Pseudomonas, Clostridioides difficile

ZERBAXA is contraindicated in patients with known serious hypersensitivity to the components of ZERBAXA (ceftolozane/tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class.

Key Points: 
  • ZERBAXA is contraindicated in patients with known serious hypersensitivity to the components of ZERBAXA (ceftolozane/tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class.
  • Additionally, Clostridium difficile-associated diarrhea (CDAD),ranging from mild diarrhea to fatal colitis, has been reported with nearly all systemic antibacterial agents, including ZERBAXA.
  • In addition, Pseudomonas aeruginosa is the most common Gram-negative pathogen in HABP/VABP and is becoming increasingly difficult to treat.
  • This approval reflects Mercks longstanding commitment to helping alleviate the burden of infectious diseases, including serious infections caused by Gram-negative pathogens.

Apotex Corp. Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection, USP 3.375 gram/vial and 4.5 gram/vial Strengths due to Elevated Levels of Impurities that may Result in Decreased Potency.

Retrieved on: 
Monday, May 14, 2018
Chemistry, Organic chemistry, Economy, Acetamides, Diketopiperazines, Penicillins, Piperacillin, Wyeth, Apotex, Tazobactam, Distribution

The affected Piperacillin and Tazobactam for Injection, USP 3.375 gram/vial and 4.5 gram/vial strengths were distributed Nationwide to wholesalers and one distributor.

Key Points: 
  • The affected Piperacillin and Tazobactam for Injection, USP 3.375 gram/vial and 4.5 gram/vial strengths were distributed Nationwide to wholesalers and one distributor.
  • Apotex Corp. has notified wholesalers/distributor by recall letter to arrange for return of any recalled product.
  • Wholesalers/retailers/hospitals/institutions with an existing inventory of the lots subject to this recall should stop use and distribution of the remaining units and quarantine immediately.
  • Customers with questions regarding this recall can contact Apotex Corp. by phone-number 1-800-706-5575 (8:30am 5:00pm, EDT Monday thru Friday) or email address [email protected] .